When Profit Makers Can Be Active Profit Takers

NEW YORK, NY / ACCESSWIRE / March 16, 2017 /
The inside investors of Exelixis and MannKind corporations have sold some of their company stock today. One Director cashed in on a $20 a share price increase, while in another company institutions investors took advantage of the continued rise in optimism over the company stock by buying even more. There are not a lot of opportunities over the life of a stock to cash in on significant upward price movements, and these are two stocks with substantial upside potential. It proves you can increase the value of your investment by either cashing out or buying in.

RDI Initiates
Coverage:

Exelixis, Inc. https://ub.rdinvesting.com/news/?ticker=EXEL

MannKind Corporation https://ub.rdinvesting.com/news/?ticker=MNKD

Exelixis stock was up $1.06 per share on Wednesday, closing at $22.80. The company works on developing therapies for cancer treatment. Its main product is cabozantinib. Other products are Cobimetinib and XL888. There are a number of positives for the company, as it has already seized 27 percent in its market group, as kidney cancer drug Cabometyx continues to win market share. Another positive that is raising the company’s stock price is the partnership arrangements they have for almost every one of their drugs. And there is still more. There are currently 13 clinical studies in progress to expand the application of cabozantinib to other treatments. Today, Director Charles Cohen sold 10,000 shares of company stock, and another director Vincent T. Marchesi sold 40,000 shares on March 10. Other institutional investors like FMR LLC, Baker BROS. Advisors LLP, Farallon Capital and Norges Bank have increased position in the company recently. The stock has a 52-week low of $3.55 a share compared to its current price of $22.96.

Access RDI’s Exelixis Research Report at: https://ub.rdinvesting.com/news/?ticker=EXEL

MannKind stock price was stagnant on Wednesday, closing at $2.02 per share, unchanged from Tuesday. The company found a number of institutional investors adding to their positions. Current, they hold 37 million of the company stock, or 19.5% of the total shares sold. The biggest owners have added to their investment. Top institutional investors Vanguard Group, Blackrock Fund Advisors, and Goldman Sachs own $6.9 million, $4.03 million, and $3 million worth of Mannkind stock respectively. The company made a presentation today at the ROTH Conference, where they reported on their current lead drug for diabetics, Alfreeza. It has an inhaler delivery system and it reports that early results are comparable to the de facto insulin injection drug for type 1 diabetics, Lantus.

Access RDI’s MannKind Research Report at: https://ub.rdinvesting.com/news/?ticker=MNKD

Our Actionable Research on Exelixis, Inc. (NASDAQ: EXEL) and MannKind Corporation (NASDAQ: MNKD) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457441